10-Q: BioAdaptives Reports Q2 2026 Results, Faces Going Concern Doubt

BioAdaptives Inc. filed its Q2 2026 10-Q, showing increased revenue but also a significant accumulated deficit and material weaknesses in internal controls, raising substantial doubt about its ability to continue as a going concern.

Summary

• BioAdaptives Inc. reported its quarterly results for the period ending June 30, 2026.
• The company experienced a net gain of $150,090 for the three months ended June 30, 2026, a significant improvement from a net loss of $157,914 in the same period of 2025.
• This improvement was largely driven by a change in the fair value of derivative liabilities, which resulted in a gain of $446,730 in Q2 2026 compared to $130,954 in Q2 2025.
• Total assets decreased to $78,767 as of June 30, 2026, from $225,901 as of December 31, 2025.
• Total liabilities also decreased to $1,844,874 from $2,355,957.
• The company has an accumulated deficit of $10,682,200 as of June 30, 2026.
• The company has identified material weaknesses in its internal control over financial reporting, including inadequate segregation of duties and insufficient written policies and procedures.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to its recurring losses and need for future capital.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the company's continued operational losses, significant accumulated deficit, and substantial doubt about its ability to continue as a going concern, despite some positive revenue trends and product development.

Positives

• Reported a net gain of $150,090 for the three months ended June 30, 2026, a significant improvement from a net loss of $157,914 in the prior year's comparable period.
• Revenue increased to $4,988 for the three months ended June 30, 2026, from $3,219 in the prior year's comparable period.
• Gross profit improved to $4,240 for the three months ended June 30, 2026, from $1,063 in the prior year's comparable period.
• The company is actively developing and launching new products, including MyndMed, Zeranovia, Xcellara, and PawPaRegen.
• The company is exploring strategic partnerships within the telehealth industry and expanding its marketing efforts, including on Amazon.
• Conversion of debt into common stock occurred, reducing convertible notes outstanding.
• The company has a plan to issue additional shares of common stock for cash and services to mitigate going concern risks.

Negatives

• The company has an accumulated deficit of $10,682,200 as of June 30, 2026.
• Total assets have significantly decreased to $78,767 as of June 30, 2026, from $225,901 as of December 31, 2025.
• Current liabilities ($1,844,874) significantly exceed current assets ($67,767), resulting in a working capital deficiency of $1,766,107 as of June 30, 2026.
• The company has identified material weaknesses in its internal control over financial reporting, leading to ineffective disclosure controls and procedures.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has defaulted on its 12% Debentures issued in 2018 and is working on an alternative resolution.
• Cash on hand was only $29,221 as of June 30, 2026, which is insufficient to operate the business at the current level for the next twelve months.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to its history of losses and need for future capital.
• The company has material weaknesses in its internal control over financial reporting, which could lead to errors in financial reporting.
• The company is in default on its 12% Debentures issued in 2018, and the resolution is uncertain.
• The company has insufficient cash to operate for the next twelve months and to achieve its business goals.
• The success of the business plan beyond the next 12 months is contingent upon obtaining additional financing, which is not guaranteed.
• The company's ability to remediate material weaknesses in internal controls is dependent on securing additional financing.

Future Outlook

The company anticipates incurring losses in the near future until all products are launched and sales are maximized. Its ability to continue as a going concern is dependent on successfully competing, operating profitably, and/or raising additional capital. Management plans to raise capital through equity markets, seek acquisitions, and generate revenue. However, there is no assurance that revenues will be sufficient to achieve profitability and positive cash flows.

Management Comments

• Management believes that increasing marketing expenses will be critical to establishing sales sufficient to cover expenses and generate a profit.
• Management anticipates using existing financing operations, which will likely require equity issuance, increases in debt, or both.
• Management's plans include raising capital through equity markets, seeking additional acquisitions, and generating revenue through its business.

Industry Context

StockSavvy.ai notes that BioAdaptives operates in the competitive health and wellness sector, focusing on natural supplements and medical devices. The company's strategy of reformulating products and launching new ones like MyndMed and Zeranovia aligns with industry trends towards personalized and science-backed wellness solutions. However, the company's financial struggles and reliance on external financing are significant headwinds in this capital-intensive industry.

Comparison to Industry Standards

• The company's revenue of $4,988 for the quarter is significantly lower than established players in the health and wellness supplement market.
• The substantial accumulated deficit of over $10 million is a critical concern when compared to companies with stable profitability.
• The reliance on derivative liability valuation for net income, as seen in the $446,730 gain in Q2 2026, is not a sustainable or typical driver of profitability for mature companies in this sector.
• The material weaknesses in internal controls are a significant deviation from industry best practices and regulatory expectations for publicly traded companies.

Corporate Governance

Legal Proceedings

• The company is in default on its 12% Debentures issued in 2018 and is working on an alternative resolution.

Related Party Transactions

• As of June 30, 2026, the company recorded $2,978 due to a related party for the payment of operating expenses on behalf of the company. This amount is non-interest bearing and due on demand.
• Employment agreements for CEO and directors involve salaries and issuance of Series D Preferred Stock for payroll compensation.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern issues, accumulated deficit, and potential dilution from future capital raises.
• Creditors may be concerned about the company's ability to meet its debt obligations, particularly given the default on 12% Debentures.
• Employees (currently one full-time executive) may face uncertainty regarding the company's long-term viability.

Next Steps

• Implement changes to enhance and improve the design of internal control over financial reporting, including appointing additional qualified personnel and adopting sufficient written policies and procedures.
• Secure additional financing to fund future operations and remediation efforts.
• Continue product development and launch efforts for new products.
• Expand marketing and sales efforts for existing and new product lines.
• Resolve outstanding debt obligations, including the defaulted 12% Debentures.

Key Dates

Recommendation

The company exhibits severe financial distress, with substantial doubt about its going concern status, significant accumulated deficit, and material weaknesses in internal controls. Despite some revenue growth and product development, the immediate financial risks and lack of clear path to profitability outweigh potential upside, suggesting a sell recommendation for seasoned investors.

Keywords

BioAdaptives, 10-Q, Quarterly Report, Financial Statements, Going Concern, Derivative Liabilities, Accumulated Deficit, Internal Controls